- Home
- LIXT vs ALLR Comparison
LIXT vs ALLR Comparison
Compare LIXT & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- ALLR
- Stock Information
- Founded
- LIXT 2005
- ALLR 2004
- Country
- LIXT United States
- ALLR United States
- Employees
- LIXT N/A
- ALLR N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- ALLR Health Care
- Exchange
- LIXT Nasdaq
- ALLR Nasdaq
- Market Cap
- LIXT 20.5M
- ALLR 20.2M
- IPO Year
- LIXT N/A
- ALLR N/A
- Fundamental
- Price
- LIXT $4.35
- ALLR $1.42
- Analyst Decision
- LIXT
- ALLR Strong Buy
- Analyst Count
- LIXT 0
- ALLR 1
- Target Price
- LIXT N/A
- ALLR $9.25
- AVG Volume (30 Days)
- LIXT 129.2K
- ALLR 333.6K
- Earning Date
- LIXT 11-07-2025
- ALLR 11-13-2025
- Dividend Yield
- LIXT N/A
- ALLR N/A
- EPS Growth
- LIXT N/A
- ALLR N/A
- EPS
- LIXT N/A
- ALLR N/A
- Revenue
- LIXT N/A
- ALLR N/A
- Revenue This Year
- LIXT N/A
- ALLR N/A
- Revenue Next Year
- LIXT N/A
- ALLR N/A
- P/E Ratio
- LIXT N/A
- ALLR N/A
- Revenue Growth
- LIXT N/A
- ALLR N/A
- 52 Week Low
- LIXT $0.64
- ALLR $0.61
- 52 Week High
- LIXT $6.26
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- LIXT 45.71
- ALLR 45.01
- Support Level
- LIXT $4.05
- ALLR $1.34
- Resistance Level
- LIXT $4.42
- ALLR $1.49
- Average True Range (ATR)
- LIXT 0.40
- ALLR 0.11
- MACD
- LIXT -0.04
- ALLR -0.02
- Stochastic Oscillator
- LIXT 41.51
- ALLR 17.39
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.